[Featured Stock] BioLeaders Plummets 15% on News of Paid-in Capital Increase
[Asia Economy Reporter Minji Lee] BioLeaders is experiencing a sharp decline following news that it will proceed with a paid-in capital increase worth 45 billion KRW to secure funds for new drug development and improve its financial structure.
At 9:30 AM on the 28th, BioLeaders was trading at 7,160 KRW on the KOSDAQ market, down 14.7% from the previous session.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
On the day, BioLeaders stated, "The funds secured through this paid-in capital increase will be used for clinical trials of the new drug pipeline and financial structure improvement," adding, "We will accelerate clinical trials for new drug development through proactive fund securing."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
